ArticleBMJ neurology open2025
Efficacy of intravenous thrombolysis in treating cortical and lacunar strokes: analysis from the Qatar Stroke Registry in a multi-ethnic population.
Article in BMJ neurology open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Intravenous thrombolysis is an effective method in treating acute ischaemic stroke, with several studies reporting improved outcomes and reduced mortality rates. However, there are limited data on whether thrombolysis is effective in treating different ischaemic stroke subtypes in the Middle East and North African region. Methods: Data of cortical and lacunar patients who received intravenous thrombolysis from the Qatar Stroke Registry were retrospectively analysed from April 2014 to January 2025. Patients were matched 1:2 for age and admission National Institute of Health Stroke Scale (NIHSS). Results: Patients with cortical stroke who received recombinant tissue-type plasminogen activator (rt-PA) had a significantly lower proportion of a poor clinical outcome at 90 days (modified Rankin Scale (mRS) score of 3-6; 41.5% vs 50.5%, p=0.002), significantly lower NIHSS score at discharge (NIHSS score >10: 23.0% vs 33.9%, p<0.001), significantly lower proportion of mortality at 90 days (4.7% vs 8.2%, p=0.02) and significantly shorter length of stay (5.2 days vs 6.0 days, p=0.01) compared with controls. In terms of outcomes for patients with lacunar stroke, there were no significant differences compared with controls for their mRS score at 90 days (p=0.054), NIHSS score at discharge (p=0.21), mortality at 90 days (p=0.67) and length of stay (p=0.34). A multivariate conditional logistic regression model revealed that high admission NIHSS score (>10) was a significant predictor of a poor functional outcome at 90 days for cortical stroke post rt-PA (p<0.001), whereas for lacunar stroke, both high admission NIHSS score (>10) and symptom onset of >3 hours were identified as significant predictors of a poor functional outcome at 90 days post rt-PA (p=0.01 for both). History of diabetes mellitus and hypertension were also significant predictors of poor clinical outcome at 90 days, but this was only observed for cortical stroke (p<0.001 and p=0.003). Conclusion: In this study, intravenous thrombolysis yielded significant clinical outcomes for patients with cortical stroke but not patients with lacunar stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.